Home Newsfeeds Chardan Capital Downgrades Oncorus to Neutral

Chardan Capital Downgrades Oncorus to Neutral

Chardan Capital analyst Matthew Barcus downgrades Oncorus (NASDAQ:ONCR) from Buy to Neutral.

byBenzinga Newsdesk

December 1, 2022

1 minute read

Chardan Capital analyst Matthew Barcus downgrades Oncorus (NASDAQ:ONCR) from Buy to Neutral.

Small-Caps Grossly Underperform Broader Market Amid This Red Flag: 5 Stocks On The Scanner

By Shanthi Rexaline

November 20, 7:13 AM

Small-cap stocks have not taken off significantly this year despite the broader market rebound, primarily due to their increasing debt burden, a report says.

CLPR

What’s Going On With G1 Therapeutics Stock?

By Erica Kollmann

May 9, 2:24 PM

According to a report, G1 Therapeutics has received and rejected multiple offers from TerSera Therapeutics. According to the report, one offer from TerSera is rumored to have a contingent value right which could value the company at between $12 and $14 per share.

GTHX

Verona Pharma To Announce Top-line Data From Phase 3 ENHANCE-1 Trial Of Nebulized Ensifentrine For COPD On Tuesday, December 20, 2022

By Benzinga Newsdesk

December 19, 5:02 PM

Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces it will report top-line Phase 3 data from its

VRNA

$1000 Invested In This Stock 15 Years Ago Would Be Worth $3,900 Today

By Benzinga Insights

July 29, 12:48 PM

Digital Realty Trust (NYSE:DLR) has outperformed the market over the past 15 years by 2.1% on an annualized basis producing an average annual return of 9.2%. Currently, Digital Realty Trust has a market capitalization of $37.62 billion.

DLR

Chardan Capital Downgrades Oncorus to Neutral

Related Posts

Small-Caps Grossly Underperform Broader Market Amid This Red Flag: 5 Stocks On The Scanner

What’s Going On With G1 Therapeutics Stock?

Verona Pharma To Announce Top-line Data From Phase 3 ENHANCE-1 Trial Of Nebulized Ensifentrine For COPD On Tuesday, December 20, 2022

$1000 Invested In This Stock 15 Years Ago Would Be Worth $3,900 Today